SG11202003585VA - Anti-vista antibody and use thereof - Google Patents

Anti-vista antibody and use thereof

Info

Publication number
SG11202003585VA
SG11202003585VA SG11202003585VA SG11202003585VA SG11202003585VA SG 11202003585V A SG11202003585V A SG 11202003585VA SG 11202003585V A SG11202003585V A SG 11202003585VA SG 11202003585V A SG11202003585V A SG 11202003585VA SG 11202003585V A SG11202003585V A SG 11202003585VA
Authority
SG
Singapore
Prior art keywords
vista antibody
vista
antibody
Prior art date
Application number
SG11202003585VA
Inventor
Youngae Lee
Sang Soon Byun
Jung Min Ha
Sungho Ahn
Keunhee Oh
Weon Sup Lee
Mi Ju Park
Eun Hee Lee
Do-Yun Kim
Jin-San Yoo
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of SG11202003585VA publication Critical patent/SG11202003585VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202003585VA 2017-10-20 2018-10-22 Anti-vista antibody and use thereof SG11202003585VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170136632 2017-10-20
PCT/KR2018/012494 WO2019078699A2 (en) 2017-10-20 2018-10-22 Anti-vista antibody and use thereof

Publications (1)

Publication Number Publication Date
SG11202003585VA true SG11202003585VA (en) 2020-05-28

Family

ID=66173724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003585VA SG11202003585VA (en) 2017-10-20 2018-10-22 Anti-vista antibody and use thereof

Country Status (12)

Country Link
US (1) US11407833B2 (en)
EP (1) EP3699193A4 (en)
JP (1) JP7009642B2 (en)
KR (1) KR102281405B1 (en)
CN (1) CN111465617B (en)
AU (1) AU2018351418B2 (en)
BR (1) BR112020007755A2 (en)
CA (1) CA3079652C (en)
MX (1) MX2020005495A (en)
RU (1) RU2750723C1 (en)
SG (1) SG11202003585VA (en)
WO (1) WO2019078699A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102630011B1 (en) 2017-01-11 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 PSGL-1 antagonists and their uses
JP7211961B2 (en) 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク Antibody that binds to VISTA at acidic pH
US10577424B1 (en) * 2019-08-15 2020-03-03 Beijing Mabworks Biotech Co., Ltd. Antibodies binding VISTA and uses thereof
WO2024053929A1 (en) * 2022-09-05 2024-03-14 주식회사 시클리드 Anti-vista monoclonal antibody and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Lab Inc Organism as carrier for "Single Chain Antibody Domain (SCAD)".
DE3852074D1 (en) 1987-03-20 1994-12-15 Creative Biomolecules Inc METHOD FOR PURIFYING RECOMBINANT POLYPEPTIDES.
JP2535066B2 (en) 1987-03-20 1996-09-18 クリエイティブ・バイオマリキュールズ・インコーポレーテッド Leader sequence for recombinant protein production
JPH02500329A (en) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド Targeted multifunctional protein
KR100883430B1 (en) 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
JP6682426B2 (en) * 2013-05-24 2020-04-15 メディミューン，エルエルシー Anti-B7-H5 antibody and use thereof
MX2016003744A (en) * 2013-10-11 2016-08-11 Us Health Tem8 antibodies and their use.
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
JOP20150008B1 (en) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
CA2988397A1 (en) * 2015-05-08 2016-11-17 Eureka Therapeutics, Inc. Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof
BR112017027870A2 (en) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv antibodies and anti-sight fragments
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017181109A1 (en) * 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof

Also Published As

Publication number Publication date
CA3079652C (en) 2022-07-19
EP3699193A2 (en) 2020-08-26
CN111465617B (en) 2023-08-25
WO2019078699A3 (en) 2019-06-06
US11407833B2 (en) 2022-08-09
RU2750723C1 (en) 2021-07-01
MX2020005495A (en) 2021-01-08
CN111465617A (en) 2020-07-28
KR102281405B1 (en) 2021-07-26
CA3079652A1 (en) 2019-04-25
JP7009642B2 (en) 2022-01-25
EP3699193A4 (en) 2022-01-26
AU2018351418B2 (en) 2021-08-26
AU2018351418A1 (en) 2020-05-14
WO2019078699A2 (en) 2019-04-25
JP2021500068A (en) 2021-01-07
US20200407449A1 (en) 2020-12-31
KR20190044563A (en) 2019-04-30
BR112020007755A2 (en) 2020-10-20

Similar Documents

Publication Publication Date Title
IL268206A (en) Bcma-targeting antibody and use thereof
IL290842A (en) Anti-cd73 antibodies and uses thereof
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
SG10201912199XA (en) Anti-tim-3 antibodies and use thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL268734A (en) Anti-lag-3 antibodies and uses thereof
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL271477A (en) Anti-cd166 antibodies and uses thereof
IL262095A (en) Anti-pacap antibodies and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
EP3541840C0 (en) Anti-hla-g antibodies and use thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
IL265689A (en) Anti-il-33 antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL263242A (en) Cytosol-penetrating antibody and use thereof
IL272476A (en) Anti-apelin antibodies and uses thereof
IL273157A (en) Axl-specific antibodies and uses thereof
IL266049A (en) Anti-o1 antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
IL266082A (en) Anti-chikv antibodies and uses thereof
IL264417A (en) Anti-o2 antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
IL274202A (en) Anti-glyco-muc1 antibodies and their uses